{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:14:53Z","timestamp":1777392893479,"version":"3.51.4"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie","award":["Unassigned"],"award-info":[{"award-number":["Unassigned"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2022-0476_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>It is important to understand what variables influence change in predicted adult height (PAH) throughout GnRHa treatment for central precocious puberty (CPP) to individualize treatment decisions and optimize care.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2022-0476_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Changes in PAH, chronological age (CA), bone age (BA), BA\/CA, and height velocity (HV) were evaluated in girls with CPP throughout treatment with leuprolide acetate (n=77). A second analysis focused on changes in the 3\u00a0years preceding the first observed BA of\u00a0\u226512\u00a0years. Relationships were characterized using plot inspection and\u00a0linear mixed-effects analyses. Association between treatment duration and last assessed PAH was examined using multiple linear regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2022-0476_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>BA\/CA and HV showed a nonlinear change during treatment, with the largest changes and improvement in PAH observed in the first 6\u201318\u00a0months. Rate of BA advancement tended to decrease more slowly in girls initiating treatment at a younger BA. On-treatment change in PAH was predicted by concurrent BA\/CA change, HV, and BA, as well as CA at treatment initiation. Last assessed PAH was positively associated with longer treatment durations (primary\/exploratory models cut-offs of\u00a0\u226533\/\u226555\u00a0months).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2022-0476_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings support individualized monitoring during GnRHa treatment. Initial response should be interpreted with caution until 6\u201318\u00a0months after treatment initiation and failure should not be assumed based on continued bone maturation in girls starting therapy at a younger age. Treatment cessation should not be automatically based on a diminishing change in PAH or HV, as ongoing treatment may result in continued increase or maintenance of PAH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2022-0476","type":"journal-article","created":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T22:06:58Z","timestamp":1670364418000},"page":"299-308","source":"Crossref","is-referenced-by-count":6,"title":["Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty"],"prefix":"10.1515","volume":"36","author":[{"given":"Marcela Vargas","family":"Trujillo","sequence":"first","affiliation":[{"name":"Department of Pediatrics , University of California San Diego , and Rady Children\u2019s Hospital , San Diego , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics , Penn State Hershey Medical Center , Hershey , PA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kent","family":"Reifschneider","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of the King\u2019s Daughters , Norfolk , VA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe F.","family":"Backeljauw","sequence":"additional","affiliation":[{"name":"Division of Endocrinology , Cincinnati Children\u2019s Hospital Medical Center and University of Cincinnati College of Medicine , Cincinnati , OH , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanja","family":"Dragnic","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Van Komen","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yu","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen O.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Pediatrics , University of California San Diego , and Rady Children\u2019s Hospital , San Diego , CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"2023033123251301276_j_jpem-2022-0476_ref_001","doi-asserted-by":"crossref","unstructured":"Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357\u201372. https:\/\/doi.org\/10.1159\/000501336.","DOI":"10.1159\/000501336"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_002","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Group, E-LGACC, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_003","doi-asserted-by":"crossref","unstructured":"Eugster, EA, Clarke, W, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007;92:1697\u2013704. https:\/\/doi.org\/10.1210\/jc.2006-2479.","DOI":"10.1210\/jc.2006-2479"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_004","doi-asserted-by":"crossref","unstructured":"Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79\u201387. https:\/\/doi.org\/10.1530\/eje-15-0590.","DOI":"10.1530\/EJE-15-0590"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_005","doi-asserted-by":"crossref","unstructured":"Kaplowitz, PB, Backeljauw, PF, Allen, DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr 2018;90:1\u20137. https:\/\/doi.org\/10.1159\/000491103.","DOI":"10.1159\/000491103"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_006","doi-asserted-by":"crossref","unstructured":"Mul, D, Oostdijk, W, Otten, BJ, Rouwe, C, Jansen, M, Delemarre-van de Waal, HA, et al.. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13:765\u201372. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.765.","DOI":"10.1515\/JPEM.2000.13.S1.765"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_007","doi-asserted-by":"crossref","unstructured":"Partsch, CJ, Heger, S, Sippell, WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German decapeptyl study group. J Pediatr Endocrinol Metab 2000;13 (1\u00a0Suppl):747\u201358. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.747.","DOI":"10.1515\/JPEM.2000.13.S1.747"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_008","doi-asserted-by":"crossref","unstructured":"Trujillo, MV, Dragnic, S, Aldridge, P, Klein, KO. Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years. J Pediatr Endocrinol Metab 2021;34:733\u20139. https:\/\/doi.org\/10.1515\/jpem-2021-0114.","DOI":"10.1515\/jpem-2021-0114"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_009","doi-asserted-by":"crossref","unstructured":"Arrigo, T, Cisternino, M, Galluzzi, F, Bertelloni, S, Pasquino, AM, Antoniazzi, F, et al.. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140\u20134. https:\/\/doi.org\/10.1530\/eje.0.1410140.","DOI":"10.1530\/eje.0.1410140"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_010","doi-asserted-by":"crossref","unstructured":"Carel, JC, Roger, M, Ispas, S, Tondu, F, Lahlou, N, Blumberg, J, et al.. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973\u20138. https:\/\/doi.org\/10.1210\/jcem.84.6.5647.","DOI":"10.1210\/jcem.84.6.5647"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_011","doi-asserted-by":"crossref","unstructured":"Oostdijk, W, Rikken, B, Schreuder, S, Otten, B, Odink, R, Rouwe, C, et al.. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist. Arch Dis Child 1996;75:292\u20137. https:\/\/doi.org\/10.1136\/adc.75.4.292.","DOI":"10.1136\/adc.75.4.292"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_012","doi-asserted-by":"crossref","unstructured":"Neely, EK, Lee, PA, Bloch, CA, Larsen, L, Yang, D, Mattia-Goldberg, C, et al.. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639. https:\/\/doi.org\/10.1186\/1687-9856-2010-398639.","DOI":"10.1186\/1687-9856-2010-398639"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_013","doi-asserted-by":"crossref","unstructured":"Lee, PA, Klein, K, Mauras, N, Lev-Vaisler, T, Bacher, P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab 2014;99:3153\u20139. https:\/\/doi.org\/10.1210\/jc.2013-4471.","DOI":"10.1210\/jc.2013-4471"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_014","doi-asserted-by":"crossref","unstructured":"Bayley, N, Pinneau, SR. Tables\u00a0for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423\u201341. https:\/\/doi.org\/10.1016\/s0022-3476(52)80205-7.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_015","doi-asserted-by":"crossref","unstructured":"Emons, J, Chagin, AS, Savendahl, L, Karperien, M, Wit, JM. Mechanisms of growth plate maturation and epiphyseal fusion. Horm Res Paediatr 2011;75:383\u201391. https:\/\/doi.org\/10.1159\/000327788.","DOI":"10.1159\/000327788"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_016","doi-asserted-by":"crossref","unstructured":"Nilsson, O, Marino, R, De Luca, F, Phillip, M, Baron, J. Endocrine regulation of the growth plate. Horm Res 2005;64:157\u201365. https:\/\/doi.org\/10.1159\/000088791.","DOI":"10.1159\/000088791"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_017","doi-asserted-by":"crossref","unstructured":"Shim, KS. Pubertal growth and epiphyseal fusion. Ann Pediatr Endocrinol Metab 2015;20:8\u201312. https:\/\/doi.org\/10.6065\/apem.2015.20.1.8.","DOI":"10.6065\/apem.2015.20.1.8"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_018","doi-asserted-by":"crossref","unstructured":"Lazar, L, Padoa, A, Phillip, M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab 2007;92:3483\u20139. https:\/\/doi.org\/10.1210\/jc.2007-0321.","DOI":"10.1210\/jc.2007-0321"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_019","doi-asserted-by":"crossref","unstructured":"Nabhan, ZM, Feezle, LK, Kunselman, AR, Johnson, NB, Lee, PA. Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. J\u00a0Pediatr Endocrinol Metab 2009;22:309\u201316. https:\/\/doi.org\/10.1515\/jpem.2009.22.4.309.","DOI":"10.1515\/JPEM.2009.22.4.309"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_020","unstructured":"Bajpai, A, Sharma, J, Kabra, M, Gupta, AK, Menon, PS. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. Indian Pediatr 2002;39:633\u20139."},{"key":"2023033123251301276_j_jpem-2022-0476_ref_021","doi-asserted-by":"crossref","unstructured":"Brito, VN, Latronico, AC, Cukier, P, Teles, MG, Silveira, LF, Arnhold, IJ, et al.. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab 2008;93:2662\u20139. https:\/\/doi.org\/10.1210\/jc.2007-2183.","DOI":"10.1210\/jc.2007-2183"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_022","doi-asserted-by":"crossref","unstructured":"Klein, KO, Barnes, KM, Jones, JV, Feuillan, PP, Cutler, GBJr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711\u20136. https:\/\/doi.org\/10.1210\/jcem.86.10.7915.","DOI":"10.1210\/jcem.86.10.7915"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_023","doi-asserted-by":"crossref","unstructured":"Li, P, Li, Y, Yang, CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis. Medicine 2014;93:e260. https:\/\/doi.org\/10.1097\/md.0000000000000260.","DOI":"10.1097\/MD.0000000000000260"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_024","doi-asserted-by":"crossref","unstructured":"Poomthavorn, P, Suphasit, R, Mahachoklertwattana, P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524\u20138. https:\/\/doi.org\/10.3109\/09513590.2010.507289.","DOI":"10.3109\/09513590.2010.507289"},{"key":"2023033123251301276_j_jpem-2022-0476_ref_025","doi-asserted-by":"crossref","unstructured":"Tanaka, T, Niimi, H, Matsuo, N, Fujieda, K, Tachibana, K, Ohyama, K, et al.. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese study group on central Precocious Puberty. J Clin Endocrinol Metab 2005;90:1371\u20136. https:\/\/doi.org\/10.1210\/jc.2004-1863.","DOI":"10.1210\/jc.2004-1863"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0476\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0476\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T12:26:08Z","timestamp":1680351968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2022-0476\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,6]]},"published-print":{"date-parts":[[2023,3,28]]}},"alternative-id":["10.1515\/jpem-2022-0476"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2022-0476","relation":{},"ISSN":["0334-018X","2191-0251"],"issn-type":[{"value":"0334-018X","type":"print"},{"value":"2191-0251","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]}}}